Tenderwize
Back to tender search

Non-exclusive Drug Discount Agreement for Somatropin

AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen·Dresden, Germany·Deadline Jul 31, 2028 · 662 days left·Open·Supplies·Framework
Sign up to saveOpen documents
Structured notice only
Original notice title

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Somatropin (ATC-Code nach WHO: H01AC01)

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

40 / 100

Complexity

20 / 100

Risk factors

No minimum purchase quantities; actual demand depends on prescription behavior and patient numbers. Revenue is unpredic...

Multiple suppliers can join, so no exclusive supply rights. Competition may reduce individual sales.

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Tender facts

Contracting authority
AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
Country
Germany
CPV
33600000 - Pharmaceutical products
Deadline
Jul 31, 2028

Overview

Moderate opportunity

Key Facts

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jul 2028
  • Supply of pharmaceutical products containing Somatropin (ATC H01AC01)
  • Non-exclusive discount agreement under §130a Abs. 8 SGB V
Show full summary

This is a non-exclusive drug discount agreement (Rabattvereinbarung) for the active substance Somatropin (ATC H01AC01) under an Open-House model, organized by AOK PLUS for Saxony and Thuringia. The contract is open to all qualified pharmaceutical companies during the participation period. No individual negotiations, no exclusivity, no guaranteed minimum purchase quantities. The agreement ends by 31 July 2028. The procedure is not a public procurement in the traditional sense; it uses an Open-House model. The first submission deadline is 7 July 2026, with rolling deadlines thereafter. No estimated value is provided. Confidentiality and strict handling of documents are required.

Risks

No minimum purchase quantities; actual demand depends on prescription behavior and patient numbers. Revenue is unpredic...

Multiple suppliers can join, so no exclusive supply rights. Competition may reduce individual sales.

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical entrepreneur as per §4 Abs. 18 AMG
  • No Russia sanctions connection per EU Regulation 833/2014

Eligibility

  • No exclusion grounds under §§123, 124 GWB

Requirements may be incomplete.

Buyer

Location

Dresden, DEU

Buyer profile

Open profile

Identifier

DE256878834

Activity

Health

Lots (1)

LOT-0001

Non-exclusive Drug Discount Agreement for Somatropin

Non-exclusive discount agreement for Somatropin (ATC H01AC01) via Open-House model. No exclusivity, no minimum volumes. Contract ends 31 July 2028.

SuppliesFrameworkEU fundedElectronic submission

Location

Dresden, Germany

Duration

Jul 2026 - Jul 2028

Category

Pharmaceutical products

Deadline

Deadline Jul 31, 2028

Procurement Details

Publication date
19 May 2026
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
345458-2026

Documents (1)

Procurement document 1

Similar tenders

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.

Dec 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30